Foritinib Succinate

丁二酸复瑞替尼

Report date: 2026/01/09 10:00:22
NME

Base Information

Drug NameForitinib Succinate
Drug Alias Name复瑞替尼Furuitini succinateSAF-189sSAF-189
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsProto-oncogene tyrosine-protein kinase ROS inhibitors
TargetsAnaplastic lymphoma kinaseProto-oncogene tyrosine-protein kinase ROS
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesFochon Pharmaceuticals LtdShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFochon Pharmaceuticals LtdFosun Wanbang (Jiangsu) Pharmaceutical Group Co LtdShanghai Fosun Pharmaceutical Industrial Development Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLymphoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A